利奈唑胺与万古霉素治疗耐甲氧西林金黄色葡萄菌肺部感染的成本-效果分析

Cost-effectiveness analysis of linezolid and vancomycin in treatment of lung infection induced by MRSA

目的比较和分析利奈唑胺与万古霉素治疗耐甲氧西林金黄色葡萄菌(MRSA)肺部感染的成本-效果。方法收集我院ICU存在MRSA感染并使用利奈唑胺或万古霉素治疗的病例资料,其中利奈唑胺治疗36例,万古霉素治疗27例,运用药物经济学中的成本-效果分析等方法对其进行分析。结果利奈唑胺和万古霉素治疗MRSA肺部感染的成本分别为41 069.76元和43 096.90元,细菌清除率分别为80%和70%,其成本-效果比分别为513.37和615.67;临床有效率分别为83%和74%,其成本-效果比分别为494.81和582.39。结论利奈唑胺治疗MRSA肺部感染的成本-效果优于万古霉素。

AIM To compare and analyse the cost-effectiveness of linezolid and vancomycin in treatment of lung infection induced by methicillin-resistant Staphylococcus aureus （MRSA） . METHODS The clinical data of the patients administrated with linezolid （n = 36） and vancomycin （n = 27） were collected in ICU, and cost- effectiveness analysis and other methods were applied for the cases. RESULTS Cost of linezolid and vancomycin in treatment of lung infection induced by MRSA was 41 069.76 yuan and 43 096.90 yuan, respectively. The bacterial eradication rates was 80% and 70% while cost-effectiveness rate was 513.37 and 615.67, respectively. The clinical efficiency was 83% and 74% while cost-effectiveness rate was 494.81 and 582.39, respectively. CONCLUSION The cost-effectiveness of linezolid is better than that of vancomycin in the treatment of lung infection induced by MRSA.